• Wondering whether Eli Lilly's share price still reflects fair value, or if expectations have started to run ahead of the fundamentals? This article breaks down what the current market price might be implying.
• Eli Lilly closed at US$1,041.65, with the stock up 3.5% over the past week and 15.4% over the past month, while the return over the last year sits at 46.7% and the 3 year gain is 149%, with a very large 5 year return of 448.2%.
• These moves have come alongside steady investor attention on Eli Lilly's drug pipeline, regulatory updates and competitive position in key treatment areas. Recent headlines have focused on how the company is positioned within major therapeutic markets and what that might mean for long term revenue potential.
• Right now, Eli Lilly has a valuation score of 3 out of 6, which means half of the checks do not currently point to the stock being undervalued. The next sections will walk through what different valuation methods are signaling and finish with a broader way to think about what "fair value" really means for this stock.

Approach 1: Eli Lilly Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today, using the idea that money received in the future is worth less than money received now.

For Eli Lilly, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $8.6b. Analyst and extrapolated projections, expressed in today’s terms, show discounted Free Cash Flow reaching around $32.2b in 2030, with intermediate discounted projections ranging from about $19.4b in 2026 up to about $33.9b in 2031.

Using these projections, the DCF model arrives at an estimated intrinsic value of $1,404.38 per share, compared with the recent share price of $1,041.65. That gap indicates the stock is priced at a 25.8% discount to this cash flow based estimate, which suggests Eli Lilly appears undervalued according to this specific model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 25.8%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Eli Lilly Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. Higher growth expectations or lower perceived risk can justify a higher P/E ratio, while slower expected growth or higher risk usually point to a lower, more conservative multiple.

Eli Lilly currently trades on a P/E of 36.75x. That sits well above the Pharmaceuticals industry average of 14.90x and also above the peer group average of 23.76x. On the face of it, the stock is priced at a premium compared with many other pharmaceutical stocks.

Simply Wall St’s Fair Ratio takes this a step further. It estimates what a P/E might reasonably be, given factors such as Eli Lilly’s earnings growth profile, profit margins, industry, market cap and company specific risks. This tends to be more tailored than a simple comparison with industry or peer averages, which do not adjust for these differences. For Eli Lilly, the Fair Ratio is 37.37x, only slightly above the current 36.75x, which points to the stock trading very close to what this framework suggests is a reasonable multiple.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Eli Lilly Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Eli Lilly to the numbers you are seeing, linking your view on its obesity and diabetes pipeline, pricing risks and long term margins to a financial forecast and a fair value that you can compare directly with the current share price.

On Simply Wall St’s Community page, Narratives let you pick or create a storyline that fits your view, then connect that story to assumptions for future revenue, earnings, margins and a fair value estimate. This can help you decide whether the stock looks cheap or expensive relative to your chosen Fair Value without needing to build a full model yourself.

These Narratives update automatically as new earnings, news and analyst models are added. For example, if you lean toward a more optimistic Eli Lilly view with higher revenue growth and a Fair Value near US$1,500, or a more cautious view closer to US$900, you can see both versions side by side, understand what each assumes about pricing, capacity and risk, and decide which story you think best fits the stock today.

For Eli Lilly, however, we will make it really easy for you with previews of two leading Eli Lilly Narratives:

Fair value: US$1,189.18 per share

Implied discount to fair value: about 12% below this narrative fair value

Revenue growth assumption: 20%

• This narrative leans on continued demand for GLP 1 drugs such as Mounjaro and Zepbound, supported by low current market penetration among an estimated 100m to 120m potential patients in the US.
• It highlights long patent protection on tirzepatide, growing insurance coverage, and a view that current production capacity is the key bottleneck, not demand.
• The author assumes revenue growth of 20% to 25% a year over the next 3 to 5 years and arrives at a fair value around US$1,200 using a 9% discount rate.

Fair value: US$899.73 per share

Implied premium to fair value: about 16% above this narrative fair value

Revenue growth assumption: 12.33%

• This narrative leans on the risk that US drug pricing reforms, discounts, and pricing parity with Europe could limit future pricing power for Eli Lilly’s obesity and diabetes drugs.
• It flags concentration in a few key treatments, possible competition from generics and biosimilars, and the chance that the long term addressable market for obesity and metabolic drugs is smaller than some forecasts assume.
• The author anchors on a bearish analyst cohort that models revenue growth of 12.3% a year, higher margins, and a future P/E of about 24x to arrive at a fair value of US$899.73, below the recent share price.

If you want to see how other investors are framing Eli Lilly’s upside and risks across different fair values, See what the community is saying about Eli Lilly.

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.